Breast Carcinoma Survival in Europe and the United States: A Population-Based Study

Milena Sant, Claudia Allemani, Franco Berrino, Michel P. Coleman, Tiiu Aareleid, Gilles Chaplain, Jan Willem Coebergh, Marc Colonna, Paolo Crosignani, Arlette Danzon, Massimo Federico, Lorenzo Gafà, Pascale Grosclaude, Guy Hédelin, Josette Macè-Lesech, Carmen Martinez Garcia, Henrik Møller, Eugenio Paci, Nicole Raverdy, Brigitte TretarreEvelyn M I Williams, A. Kupp, C. Exbrayat, M. Mercier, E. Artioli, A. Barchielli, G. Gatta, M. Sant, C. Allemani, D. Speciale, M. R. Ruzza, E. Frassoldi, R. Capocaccia, A. Verdecchia, L. Gafà, R. Tumino, M. La Rosa, A. Voogd, J. Bell, J. Youngson

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Breast carcinoma survival rates were found to be higher in the U.S. than in Europe. METHODS. Multiple regression analysis of breast carcinoma survival rates among women diagnosed between 1990 and 1992 was performed using clinical data from population-based case series from the Surveillance, Epidemiogy, and End Results (SEER) program (13,172 women) and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS. Early-stage tumors (T1N0M0) were more frequent in the SEER data (41% of cases) than in the EUROCARE data (29%). In the SEER data, early tumors were more frequent in women age ≥ 65 years (43%) than in younger women (38%), whereas the reverse was true in the European data (25% vs. 31%). In both case series, > 90% of women underwent surgery and 81-82% underwent lymphadenectomy, but the number of axillary lymph nodes evaluated was higher in the SEER data than in the EUROCARE data. The 5-year survival rate was higher in the U.S. case series (89%) than in the European series (79%). This differential was observed for each stage category evaluated: early (T1N0M0), large lymph node-negative (T2-3N0M0), lymph node-positive (T1-3N+M0), locally advanced (T4M0), and metastatic (M1) tumors. The overall relative excess risk (RER) of death was significantly higher (RER, 1.37; 95% confidence interval [95% CI], 1.25-1.50) among European women compared with U.S. women (referent group). Adjustment for stage, age, surgery, and the number of lymph nodes evaluated explained most of the excess risk (RER, 1.07; 95% CI, 0.98-1.17). CONCLUSIONS. Transatlantic differences in the 5-year survival rates for women diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly to differences in stage of disease. Resources should be invested to achieve earlier diagnosis of breast carcinoma in Europe, especially for elderly women.

Original languageEnglish
Pages (from-to)715-722
Number of pages8
JournalCancer
Volume100
Issue number4
DOIs
Publication statusPublished - Feb 15 2004

Fingerprint

Breast Neoplasms
Survival
Population
Survival Rate
Lymph Nodes
Neoplasms
Confidence Intervals
Lymph Node Excision
Early Diagnosis
Patient Care
Regression Analysis

Keywords

  • Breast carcinoma
  • Cancer registries
  • Europe
  • Stage
  • Survival
  • U.S.

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sant, M., Allemani, C., Berrino, F., Coleman, M. P., Aareleid, T., Chaplain, G., ... Youngson, J. (2004). Breast Carcinoma Survival in Europe and the United States: A Population-Based Study. Cancer, 100(4), 715-722. https://doi.org/10.1002/cncr.20038

Breast Carcinoma Survival in Europe and the United States : A Population-Based Study. / Sant, Milena; Allemani, Claudia; Berrino, Franco; Coleman, Michel P.; Aareleid, Tiiu; Chaplain, Gilles; Coebergh, Jan Willem; Colonna, Marc; Crosignani, Paolo; Danzon, Arlette; Federico, Massimo; Gafà, Lorenzo; Grosclaude, Pascale; Hédelin, Guy; Macè-Lesech, Josette; Martinez Garcia, Carmen; Møller, Henrik; Paci, Eugenio; Raverdy, Nicole; Tretarre, Brigitte; Williams, Evelyn M I; Kupp, A.; Exbrayat, C.; Mercier, M.; Artioli, E.; Barchielli, A.; Gatta, G.; Sant, M.; Allemani, C.; Speciale, D.; Ruzza, M. R.; Frassoldi, E.; Capocaccia, R.; Verdecchia, A.; Gafà, L.; Tumino, R.; La Rosa, M.; Voogd, A.; Bell, J.; Youngson, J.

In: Cancer, Vol. 100, No. 4, 15.02.2004, p. 715-722.

Research output: Contribution to journalArticle

Sant, M, Allemani, C, Berrino, F, Coleman, MP, Aareleid, T, Chaplain, G, Coebergh, JW, Colonna, M, Crosignani, P, Danzon, A, Federico, M, Gafà, L, Grosclaude, P, Hédelin, G, Macè-Lesech, J, Martinez Garcia, C, Møller, H, Paci, E, Raverdy, N, Tretarre, B, Williams, EMI, Kupp, A, Exbrayat, C, Mercier, M, Artioli, E, Barchielli, A, Gatta, G, Sant, M, Allemani, C, Speciale, D, Ruzza, MR, Frassoldi, E, Capocaccia, R, Verdecchia, A, Gafà, L, Tumino, R, La Rosa, M, Voogd, A, Bell, J & Youngson, J 2004, 'Breast Carcinoma Survival in Europe and the United States: A Population-Based Study', Cancer, vol. 100, no. 4, pp. 715-722. https://doi.org/10.1002/cncr.20038
Sant M, Allemani C, Berrino F, Coleman MP, Aareleid T, Chaplain G et al. Breast Carcinoma Survival in Europe and the United States: A Population-Based Study. Cancer. 2004 Feb 15;100(4):715-722. https://doi.org/10.1002/cncr.20038
Sant, Milena ; Allemani, Claudia ; Berrino, Franco ; Coleman, Michel P. ; Aareleid, Tiiu ; Chaplain, Gilles ; Coebergh, Jan Willem ; Colonna, Marc ; Crosignani, Paolo ; Danzon, Arlette ; Federico, Massimo ; Gafà, Lorenzo ; Grosclaude, Pascale ; Hédelin, Guy ; Macè-Lesech, Josette ; Martinez Garcia, Carmen ; Møller, Henrik ; Paci, Eugenio ; Raverdy, Nicole ; Tretarre, Brigitte ; Williams, Evelyn M I ; Kupp, A. ; Exbrayat, C. ; Mercier, M. ; Artioli, E. ; Barchielli, A. ; Gatta, G. ; Sant, M. ; Allemani, C. ; Speciale, D. ; Ruzza, M. R. ; Frassoldi, E. ; Capocaccia, R. ; Verdecchia, A. ; Gafà, L. ; Tumino, R. ; La Rosa, M. ; Voogd, A. ; Bell, J. ; Youngson, J. / Breast Carcinoma Survival in Europe and the United States : A Population-Based Study. In: Cancer. 2004 ; Vol. 100, No. 4. pp. 715-722.
@article{7c8dafc3f6bc494caceba494219a01c9,
title = "Breast Carcinoma Survival in Europe and the United States: A Population-Based Study",
abstract = "BACKGROUND. Breast carcinoma survival rates were found to be higher in the U.S. than in Europe. METHODS. Multiple regression analysis of breast carcinoma survival rates among women diagnosed between 1990 and 1992 was performed using clinical data from population-based case series from the Surveillance, Epidemiogy, and End Results (SEER) program (13,172 women) and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS. Early-stage tumors (T1N0M0) were more frequent in the SEER data (41{\%} of cases) than in the EUROCARE data (29{\%}). In the SEER data, early tumors were more frequent in women age ≥ 65 years (43{\%}) than in younger women (38{\%}), whereas the reverse was true in the European data (25{\%} vs. 31{\%}). In both case series, > 90{\%} of women underwent surgery and 81-82{\%} underwent lymphadenectomy, but the number of axillary lymph nodes evaluated was higher in the SEER data than in the EUROCARE data. The 5-year survival rate was higher in the U.S. case series (89{\%}) than in the European series (79{\%}). This differential was observed for each stage category evaluated: early (T1N0M0), large lymph node-negative (T2-3N0M0), lymph node-positive (T1-3N+M0), locally advanced (T4M0), and metastatic (M1) tumors. The overall relative excess risk (RER) of death was significantly higher (RER, 1.37; 95{\%} confidence interval [95{\%} CI], 1.25-1.50) among European women compared with U.S. women (referent group). Adjustment for stage, age, surgery, and the number of lymph nodes evaluated explained most of the excess risk (RER, 1.07; 95{\%} CI, 0.98-1.17). CONCLUSIONS. Transatlantic differences in the 5-year survival rates for women diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly to differences in stage of disease. Resources should be invested to achieve earlier diagnosis of breast carcinoma in Europe, especially for elderly women.",
keywords = "Breast carcinoma, Cancer registries, Europe, Stage, Survival, U.S.",
author = "Milena Sant and Claudia Allemani and Franco Berrino and Coleman, {Michel P.} and Tiiu Aareleid and Gilles Chaplain and Coebergh, {Jan Willem} and Marc Colonna and Paolo Crosignani and Arlette Danzon and Massimo Federico and Lorenzo Gaf{\`a} and Pascale Grosclaude and Guy H{\'e}delin and Josette Mac{\`e}-Lesech and {Martinez Garcia}, Carmen and Henrik M{\o}ller and Eugenio Paci and Nicole Raverdy and Brigitte Tretarre and Williams, {Evelyn M I} and A. Kupp and C. Exbrayat and M. Mercier and E. Artioli and A. Barchielli and G. Gatta and M. Sant and C. Allemani and D. Speciale and Ruzza, {M. R.} and E. Frassoldi and R. Capocaccia and A. Verdecchia and L. Gaf{\`a} and R. Tumino and {La Rosa}, M. and A. Voogd and J. Bell and J. Youngson",
year = "2004",
month = "2",
day = "15",
doi = "10.1002/cncr.20038",
language = "English",
volume = "100",
pages = "715--722",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Breast Carcinoma Survival in Europe and the United States

T2 - A Population-Based Study

AU - Sant, Milena

AU - Allemani, Claudia

AU - Berrino, Franco

AU - Coleman, Michel P.

AU - Aareleid, Tiiu

AU - Chaplain, Gilles

AU - Coebergh, Jan Willem

AU - Colonna, Marc

AU - Crosignani, Paolo

AU - Danzon, Arlette

AU - Federico, Massimo

AU - Gafà, Lorenzo

AU - Grosclaude, Pascale

AU - Hédelin, Guy

AU - Macè-Lesech, Josette

AU - Martinez Garcia, Carmen

AU - Møller, Henrik

AU - Paci, Eugenio

AU - Raverdy, Nicole

AU - Tretarre, Brigitte

AU - Williams, Evelyn M I

AU - Kupp, A.

AU - Exbrayat, C.

AU - Mercier, M.

AU - Artioli, E.

AU - Barchielli, A.

AU - Gatta, G.

AU - Sant, M.

AU - Allemani, C.

AU - Speciale, D.

AU - Ruzza, M. R.

AU - Frassoldi, E.

AU - Capocaccia, R.

AU - Verdecchia, A.

AU - Gafà, L.

AU - Tumino, R.

AU - La Rosa, M.

AU - Voogd, A.

AU - Bell, J.

AU - Youngson, J.

PY - 2004/2/15

Y1 - 2004/2/15

N2 - BACKGROUND. Breast carcinoma survival rates were found to be higher in the U.S. than in Europe. METHODS. Multiple regression analysis of breast carcinoma survival rates among women diagnosed between 1990 and 1992 was performed using clinical data from population-based case series from the Surveillance, Epidemiogy, and End Results (SEER) program (13,172 women) and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS. Early-stage tumors (T1N0M0) were more frequent in the SEER data (41% of cases) than in the EUROCARE data (29%). In the SEER data, early tumors were more frequent in women age ≥ 65 years (43%) than in younger women (38%), whereas the reverse was true in the European data (25% vs. 31%). In both case series, > 90% of women underwent surgery and 81-82% underwent lymphadenectomy, but the number of axillary lymph nodes evaluated was higher in the SEER data than in the EUROCARE data. The 5-year survival rate was higher in the U.S. case series (89%) than in the European series (79%). This differential was observed for each stage category evaluated: early (T1N0M0), large lymph node-negative (T2-3N0M0), lymph node-positive (T1-3N+M0), locally advanced (T4M0), and metastatic (M1) tumors. The overall relative excess risk (RER) of death was significantly higher (RER, 1.37; 95% confidence interval [95% CI], 1.25-1.50) among European women compared with U.S. women (referent group). Adjustment for stage, age, surgery, and the number of lymph nodes evaluated explained most of the excess risk (RER, 1.07; 95% CI, 0.98-1.17). CONCLUSIONS. Transatlantic differences in the 5-year survival rates for women diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly to differences in stage of disease. Resources should be invested to achieve earlier diagnosis of breast carcinoma in Europe, especially for elderly women.

AB - BACKGROUND. Breast carcinoma survival rates were found to be higher in the U.S. than in Europe. METHODS. Multiple regression analysis of breast carcinoma survival rates among women diagnosed between 1990 and 1992 was performed using clinical data from population-based case series from the Surveillance, Epidemiogy, and End Results (SEER) program (13,172 women) and the European Concerted Action on survival and Care of Cancer Patients (EUROCARE) project (4478 women). RESULTS. Early-stage tumors (T1N0M0) were more frequent in the SEER data (41% of cases) than in the EUROCARE data (29%). In the SEER data, early tumors were more frequent in women age ≥ 65 years (43%) than in younger women (38%), whereas the reverse was true in the European data (25% vs. 31%). In both case series, > 90% of women underwent surgery and 81-82% underwent lymphadenectomy, but the number of axillary lymph nodes evaluated was higher in the SEER data than in the EUROCARE data. The 5-year survival rate was higher in the U.S. case series (89%) than in the European series (79%). This differential was observed for each stage category evaluated: early (T1N0M0), large lymph node-negative (T2-3N0M0), lymph node-positive (T1-3N+M0), locally advanced (T4M0), and metastatic (M1) tumors. The overall relative excess risk (RER) of death was significantly higher (RER, 1.37; 95% confidence interval [95% CI], 1.25-1.50) among European women compared with U.S. women (referent group). Adjustment for stage, age, surgery, and the number of lymph nodes evaluated explained most of the excess risk (RER, 1.07; 95% CI, 0.98-1.17). CONCLUSIONS. Transatlantic differences in the 5-year survival rates for women diagnosed with breast carcinoma between 1990 and 1992 were attributable mainly to differences in stage of disease. Resources should be invested to achieve earlier diagnosis of breast carcinoma in Europe, especially for elderly women.

KW - Breast carcinoma

KW - Cancer registries

KW - Europe

KW - Stage

KW - Survival

KW - U.S.

UR - http://www.scopus.com/inward/record.url?scp=10744232916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744232916&partnerID=8YFLogxK

U2 - 10.1002/cncr.20038

DO - 10.1002/cncr.20038

M3 - Article

C2 - 14770426

AN - SCOPUS:10744232916

VL - 100

SP - 715

EP - 722

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -